A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

Rohit Lal, James Dickson, David Cunningham, Ian Chau, Andrew R Norman, Paul J Ross, Clare Topham, Gary Middleton, Mark Hill, Jacqui Oates

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.
Original languageEnglish
Pages (from-to)3023-31
Number of pages9
JournalJournal of Clinical Oncology
Volume22
Issue number15
DOIs
Publication statusPublished - 2004

Fingerprint

Dive into the research topics of 'A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this